244 related articles for article (PubMed ID: 10933051)
1. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.
Chahlavi A; Todo T; Martuza RL; Rabkin SD
Neoplasia; 1999 Jun; 1(2):162-9. PubMed ID: 10933051
[TBL] [Abstract][Full Text] [Related]
2. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
3. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207).
Carew JF; Kooby DA; Halterman MW; Federoff HJ; Fong Y
Hum Gene Ther; 1999 Jul; 10(10):1599-606. PubMed ID: 10428205
[TBL] [Abstract][Full Text] [Related]
4. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.
Cinatl J; Cinatl J; Michaelis M; Kabickova H; Kotchetkov R; Vogel JU; Doerr HW; Klingebiel T; Driever PH
Cancer Res; 2003 Apr; 63(7):1508-14. PubMed ID: 12670897
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.
Mace AT; Harrow SJ; Ganly I; Brown SM
Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
Nakano K; Todo T; Chijiiwa K; Tanaka M
Mol Ther; 2001 Apr; 3(4):431-7. PubMed ID: 11319903
[TBL] [Abstract][Full Text] [Related]
8. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.
Toda M; Rabkin SD; Martuza RL
Hum Gene Ther; 1998 Oct; 9(15):2177-85. PubMed ID: 9794202
[TBL] [Abstract][Full Text] [Related]
9. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.
Lin SF; Gao SP; Price DL; Li S; Chou TC; Singh P; Huang YY; Fong Y; Wong RJ
Clin Cancer Res; 2008 Mar; 14(5):1519-28. PubMed ID: 18316577
[TBL] [Abstract][Full Text] [Related]
10. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus.
Wong RJ; Kim SH; Joe JK; Shah JP; Johnson PA; Fong Y
J Am Coll Surg; 2001 Jul; 193(1):12-21. PubMed ID: 11442249
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin enhances the efficacy of 5-aminolevulinic acid mediated photodynamic therapy in human head and neck squamous cell carcinoma.
Ahn JC; Biswas R; Mondal A; Lee YK; Chung PS
Gen Physiol Biophys; 2014; 33(1):53-62. PubMed ID: 23846261
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207.
Oyama M; Ohigashi T; Hoshi M; Murai M; Uyemura K; Yazaki T
J Urol; 2001 Apr; 165(4):1274-8. PubMed ID: 11257700
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Nakano K; Todo T; Zhao G; Yamaguchi K; Kuroki S; Cohen JB; Glorioso JC; Tanaka M
J Gene Med; 2005 May; 7(5):638-48. PubMed ID: 15754306
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes.
Carew JF; Kooby DA; Halterman MW; Kim SH; Federoff HJ; Fong Y
Mol Ther; 2001 Sep; 4(3):250-6. PubMed ID: 11545616
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Todo T; Rabkin SD; Chahlavi A; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2869-78. PubMed ID: 10584932
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
17. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma.
Goebel EA; Davidson BL; Graham SM; Kern JA
Otolaryngol Head Neck Surg; 1998 Oct; 119(4):331-6. PubMed ID: 9781985
[TBL] [Abstract][Full Text] [Related]
18. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
[TBL] [Abstract][Full Text] [Related]
19. Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation.
McNally LR; Rosenthal EL; Zhang W; Buchsbaum DJ
Cancer Gene Ther; 2009 Mar; 16(3):246-55. PubMed ID: 18846112
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]